Study Design Streptococcal Cell Wall Induced Arthritis - MorphoSys

More documents

Recommendations

Info

MOR103 Antibody Stage Outcome � Generation of a fully human antibody � � High affinity to human GM-CSF � � Inhibition of GM-CSF mediated cellular mechanisms � � No off target cross-reactivity � � Binds rhesus and rat GM-CSF � 8 HAH, New York, Nov 2008 | © MorphoSys AG
MOR103 In Vivo Antibody Efficacy 9 Study Design Streptococcal Cell Wall Induced Arthritis (SCW IA) � Treatment: MOR103 dosed at 10, 20 and 50 mg/kg once i.p. 2h before intro-articular administration of SCW fragments to male Wistar rats (right knee) � RA Parameters: Knee joint swelling (right/left knee ratio), and histopathology (PMN cell influx), synovial fluid and serum cytokine levels MOR103 controlled arthritis in the SCW model Recognised anti-cytokine inhibitor model for RA therapeutic development* *FDA (1997) http://www.fda.gov/cder/guidance/raguide.pdf HAH, New York, Nov 2008 | © MorphoSys AG
Page 1 and 2: Development of a HuCAL GOLD ® huma
Page 3 and 4: Introduction � MOR103: human mono
Page 5 and 6: MOR103 Antibody Selection* 5 H-CDR2
Page 7: MOR103 Antibody Cross Reactivity 7
Page 11 and 12: MOR103 Antibody Efficacy - Synovial
Page 13 and 14: MOR103 Antibody Toxicology 13 Rhesu
Page 15 and 16: MOR103 Antibody Manufacture � PER
Page 17 and 18: MOR103 Antibody Stage Outcome � G
Page 19 and 20: Acknowledgments 19 MorphoSys, D Rob
Page 21: Thank You www.morphosys.com Matthew

Study Design Streptococcal Cell Wall Induced Arthritis - MorphoSys

Create successful ePaper yourself

Delete template?

Save as template?